【摘要】：目的回顧性分析雷替曲賽為基礎(chǔ)化療方案治療晚期原發(fā)性肝癌的療效及安全性。方法 31例原發(fā)性肝癌患者,均接受以雷替曲塞為基礎(chǔ)方案化療,其中二線治療14例,三線及以上治療17例,方案包括雷替曲塞聯(lián)合伊立替康(TOMIRI)、雷替曲塞聯(lián)合奧沙利鉑(TOMOX)、雷替曲塞聯(lián)合吉西他濱(TOMGEM)、雷替曲塞單藥(RTX)。按照RECIST1.1版標(biāo)準(zhǔn)評價客觀療效,按照NCICTC 4.0版標(biāo)準(zhǔn)評價不良反應(yīng)。結(jié)果 31例患者完成1周期以上的化療,均可評價療效,其中無完全和部分緩解患者,13例患者穩(wěn)定(SD),18例患者進(jìn)展(PD),有效率(RR)為0%,疾病控制率(DCR)為41.9%,中位TTP(m TTP)為63天,中位OS(m OS)為189天。常見的不良反應(yīng)為骨髓抑制及消化道反應(yīng),多為Ⅰ~Ⅱ級,患者均可耐受。結(jié)論雷替曲塞為基礎(chǔ)化療方案對標(biāo)準(zhǔn)治療失敗的晚期原發(fā)性肝癌仍有一定的疾病控制率,且安全性良好,值得進(jìn)一步深入研究。
[Abstract]:Objective to retrospectively analyze the efficacy and safety of Ritripxil-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma (HCC). Methods Thirty-one patients with primary liver cancer were treated with retitroxil-based chemotherapy, of which 14 patients were treated with second-line therapy and 17 patients were treated with third-line or more. The regimen included Ratetrexil combined with irinotecan (TOMIRI),). Rettrexil combined with oxaliplatin (TOMOX), and gemcitabine (TOMGEM), (RTX). Objective curative effect was evaluated according to RECIST1.1 standard and adverse reaction was evaluated according to NCICTC 4.0 standard. Results 31 patients completed more than one cycle of chemotherapy, and all of them could evaluate the efficacy. There were no complete and partial remission in them. The effective rate of advanced (PD), in 18 patients with stable (SD), was 0%, and the effective rate of (RR) was 0% in 18 patients with stable remission. The disease control rate (DCR) was 41.9%, the median TTP (m TTP) was 63 days and the median OS (m OS) was 189 days. The common adverse reactions were myelosuppression and alimentary tract reactions, most of which were grade 鈪，

本文編號：2435226